Why the study?
Does antithrombotic therapy prevent recurrent ischemic stroke, myocardial infarction, and vascular death in patients with a history of ischemic stroke?
Does antithrombotic therapy prevent recurrent ischemic stroke, myocardial infarction, and vascular death in patients with a history of ischemic stroke?
This review summarizes the evidence and guideline recommendations for using antiplatelet and anticoagulant therapies in the secondary prevention of ischemic stroke.
Supports guideline-directed antithrombotic selection by stroke etiology; leaves open comparative effectiveness of emerging agents.
The causes of ischemic stroke are widely diverse, ranging from large artery atherosclerosis to cardioembolism, and it is important to use preventive therapy toward the goal reducing the future risk of recurrent ischemic stroke, myocardial infarction, and vascular death. Antithrombotic therapy is one of the fundamental medical approaches for secondary prevention of ischemic stroke, which is broadly divided into two general categories, those that exert their effect via platelet inhibition (antiplatelet agents), and those that influence various factors in the clotting cascade (anticoagulants). In general, the clinical guidelines recommend antiplatelet agents for patients with non-cardioembolic stroke, while anticoagulants is indicated for patients with presumed or proven cardioembolic stroke. Many clinical trials have attempted to test the efficacy and safety of antithrombotics in ischemic stroke. This review will discuss on currently available antithrombotic agents that have demonstrated efficacy for secondary prevention of ischemic stroke. (Brain & NeuroRehabilitation 2014; 7: 76-85)
No takes yet. Share an insight, caveat, or question.
Cho et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: